Cargando…
Insights from patients screened but not randomised in the HYPERION trial
BACKGROUND: Few data are available about outcomes of patients screened for, but not enrolled in, randomised clinical trials. METHODS: We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 °C to 37 °C in patients comatose after cardiac arrest in non-s...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590986/ https://www.ncbi.nlm.nih.gov/pubmed/34778914 http://dx.doi.org/10.1186/s13613-021-00947-w |
_version_ | 1784599112166932480 |
---|---|
author | Lascarrou, J. B. Muller, Gregoire Quenot, Jean-Pierre Massart, Nicolas Landais, Mickael Asfar, Pierre Frat, Jean-Pierre Chakarian, Jean-Charles Sirodot, Michel Francois, Bruno Grillet, Guillaume Vimeux, Sylvie Delahaye, Arnaud Legriel, Stéphane Thevenin, Didier Reignier, Jean Colin, Gwenhael |
author_facet | Lascarrou, J. B. Muller, Gregoire Quenot, Jean-Pierre Massart, Nicolas Landais, Mickael Asfar, Pierre Frat, Jean-Pierre Chakarian, Jean-Charles Sirodot, Michel Francois, Bruno Grillet, Guillaume Vimeux, Sylvie Delahaye, Arnaud Legriel, Stéphane Thevenin, Didier Reignier, Jean Colin, Gwenhael |
author_sort | Lascarrou, J. B. |
collection | PubMed |
description | BACKGROUND: Few data are available about outcomes of patients screened for, but not enrolled in, randomised clinical trials. METHODS: We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 °C to 37 °C in patients comatose after cardiac arrest in non-shockable rhythm, due to any cause. A good neurological outcome was defined as a day-90 Cerebral Performance Category score of 1 or 2. RESULTS: Of the 1144 patients with non-inclusion criteria, 1130 had day-90 information and, among these, 158 (14%) had good functional outcomes, compared to 7.9% overall in the HYPERION trial (10.2% with and 5.7% without hypothermia). Considerable centre-to-centre variability was found in the proportion of non-included patients who received hypothermia (0% to 83.8%) and who had good day-90 functional outcomes (0% to 31.3%). The proportion of patients with a good day-90 functional outcome was significantly higher with than without hypothermia (18.5% vs. 11.9%, P = 0.003). CONCLUSION: Our finding of better functional outcomes without than with inclusion in the HYPERION trial, despite most non-inclusion criteria being of adverse prognostic significance (e.g., long no-flow and low-flow times and haemodynamic instability), raises important questions about the choice of patient selection criteria and the applicability of trial results to everyday practice. At present, reserving hypothermia for patients without predictors of poor prognosis seems open to criticism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-021-00947-w. |
format | Online Article Text |
id | pubmed-8590986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85909862021-11-24 Insights from patients screened but not randomised in the HYPERION trial Lascarrou, J. B. Muller, Gregoire Quenot, Jean-Pierre Massart, Nicolas Landais, Mickael Asfar, Pierre Frat, Jean-Pierre Chakarian, Jean-Charles Sirodot, Michel Francois, Bruno Grillet, Guillaume Vimeux, Sylvie Delahaye, Arnaud Legriel, Stéphane Thevenin, Didier Reignier, Jean Colin, Gwenhael Ann Intensive Care Research BACKGROUND: Few data are available about outcomes of patients screened for, but not enrolled in, randomised clinical trials. METHODS: We retrospectively reviewed patients who had non-inclusion criteria for the HYPERION trial comparing 33 °C to 37 °C in patients comatose after cardiac arrest in non-shockable rhythm, due to any cause. A good neurological outcome was defined as a day-90 Cerebral Performance Category score of 1 or 2. RESULTS: Of the 1144 patients with non-inclusion criteria, 1130 had day-90 information and, among these, 158 (14%) had good functional outcomes, compared to 7.9% overall in the HYPERION trial (10.2% with and 5.7% without hypothermia). Considerable centre-to-centre variability was found in the proportion of non-included patients who received hypothermia (0% to 83.8%) and who had good day-90 functional outcomes (0% to 31.3%). The proportion of patients with a good day-90 functional outcome was significantly higher with than without hypothermia (18.5% vs. 11.9%, P = 0.003). CONCLUSION: Our finding of better functional outcomes without than with inclusion in the HYPERION trial, despite most non-inclusion criteria being of adverse prognostic significance (e.g., long no-flow and low-flow times and haemodynamic instability), raises important questions about the choice of patient selection criteria and the applicability of trial results to everyday practice. At present, reserving hypothermia for patients without predictors of poor prognosis seems open to criticism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13613-021-00947-w. Springer International Publishing 2021-11-14 /pmc/articles/PMC8590986/ /pubmed/34778914 http://dx.doi.org/10.1186/s13613-021-00947-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Lascarrou, J. B. Muller, Gregoire Quenot, Jean-Pierre Massart, Nicolas Landais, Mickael Asfar, Pierre Frat, Jean-Pierre Chakarian, Jean-Charles Sirodot, Michel Francois, Bruno Grillet, Guillaume Vimeux, Sylvie Delahaye, Arnaud Legriel, Stéphane Thevenin, Didier Reignier, Jean Colin, Gwenhael Insights from patients screened but not randomised in the HYPERION trial |
title | Insights from patients screened but not randomised in the HYPERION trial |
title_full | Insights from patients screened but not randomised in the HYPERION trial |
title_fullStr | Insights from patients screened but not randomised in the HYPERION trial |
title_full_unstemmed | Insights from patients screened but not randomised in the HYPERION trial |
title_short | Insights from patients screened but not randomised in the HYPERION trial |
title_sort | insights from patients screened but not randomised in the hyperion trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590986/ https://www.ncbi.nlm.nih.gov/pubmed/34778914 http://dx.doi.org/10.1186/s13613-021-00947-w |
work_keys_str_mv | AT lascarroujb insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT mullergregoire insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT quenotjeanpierre insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT massartnicolas insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT landaismickael insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT asfarpierre insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT fratjeanpierre insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT chakarianjeancharles insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT sirodotmichel insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT francoisbruno insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT grilletguillaume insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT vimeuxsylvie insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT delahayearnaud insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT legrielstephane insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT thevenindidier insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT reignierjean insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT colingwenhael insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial AT insightsfrompatientsscreenedbutnotrandomisedinthehyperiontrial |